Stock Taper
CMMB
CHEMOMAB THERAPEUTICS LTD.
NASDAQ
$2.71
▼ DOWN 0.37% (-0.01)

KEY STATISTICS

Market Cap$16.68 M
52w High$3.58
52w Low$1.35
Dividend Yield
Frequency
P/E-1.67
Volume105.01K
Shares Out.6.16M

COMPANY

LEADERSHIP

Adi Mor George
CHIEF EXECUTIVE
Adi Mor George

COMPENSATION 2026

Salary$192
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$492

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 12, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
12

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.
NOV
6
FRI

SPLIT RECORD

DATETYPERATIO
2025-08-26Reverse1:4
2021-03-17Reverse1:16

PRICE

$2.71 ▼ DOWN 0.37% (−$0.01)
OVERLAYS
$2.70$2.77$2.859:39 AM10:42 AM11:46 AM12:49 PM1:52 PM2:56 PM3:59 PM2.71

About Chemomab Therapeutics Ltd.

https://www.chemomab.com ↗

Chemomab Therapeutics Ltd., a Tel Aviv-based clinical-stage biotech founded in 2011, develops therapeutics like its lead candidate CM-101, a monoclonal antibody targeting chemokine CCL24 for inflammation and fibrosis-related diseases such as PSC a...

INDUSTRY

Biotechnology

A PRODUCT CHEMOMAB THERAPEUTICS LTD. IS KNOWN FOR

Nebokitug (CM-101)
Nebokitug (CM-101)

Nebokitug is Chemomab's lead monoclonal antibody targeting CCL24 to treat rare fibro-inflammatory diseases, primarily Primary Sclerosing Cholangitis (PSC).

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

DIRECTOR
Melincoff Gwen A
· 8.6K shares
2026-06-01
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mor George Adi
Purchase · 4.9K shares
2026-05-29
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mor George Adi
Purchase · 4.9K shares
2026-05-29
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mor George Adi
Sale · 31.7K shares
2026-05-29

SECTORS PEERS

PEERPRICE
KZIA$13.58COMPARE
BIVI$2.16COMPARE
GLMD$4.17COMPARE
INM$1.38COMPARE
ELAB$5.31COMPARE
XRTX$2.34COMPARE
CERO$0.01COMPARE
OCEA$0.00COMPARE